Application of Edaravone in Patients with Epidural Hematoma after Minimally Invasive Drainage of Intracranial Hematoma

Objective This study aimed to explore the effects of edaravone on neurological function and the inflammation-oxidative stress response in patients with epidural hematoma treated with minimally invasive drainage of intracranial hematoma. Methods A total of 102 patients with epidural hematoma treated with minimally invasive drainage of intracranial hematoma were prospectively and randomly divided into a conventional treatment group and an edaravone group, with 51 cases in each group. The differences in serum inflammatory factors, oxidative stress, and inflammation-oxidative stress indicators between the two groups were compared. The National Institutes of Health Stroke Scale (NIHSS) and modified Barthel index (MBI) were used to evaluate patients, neurological function and daily mobility, respectively. Results The hospital stay was significantly shorter in the edaravone group compared to the conventional treatment group (P＜0.05). After treatment, the levels of serum high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase (MMP)-9/-12, homocysteine (Hcy), malondialdehyde (MDA), and the NIHSS score in the edaravone group were significantly lower than those in the conventional treatment group (P＜0.05). The levels of superoxide dismutase (SOD), glutathione peroxidase (GSH- Px), and MBI score were significantly higher in the edaravone group than those in the conventional treatmentl group (P＜0.05). Conclusion Edaravone can significantly improve the neurological function of patients with epidural hematoma after minimally invasive drainage of intracranial hematoma, reduce the levels of inflammatory factors, enhance the antioxidant capacity, and improve patients, ability to perform daily activities.